These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 30415318)

  • 1. Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.
    Grativvol RS; Cavalcante WCP; Castro LHM; Nitrini R; Simabukuro MM
    Curr Oncol Rep; 2018 Nov; 20(11):92. PubMed ID: 30415318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraneoplastic epilepsy.
    Serafini A; Lukas RV; VanHaerents S; Warnke P; Tao JX; Rose S; Wu S
    Epilepsy Behav; 2016 Aug; 61():51-58. PubMed ID: 27304613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Paraneoplastic neurological syndromes : A current summary].
    De Simoni D; Höftberger R
    Internist (Berl); 2018 Feb; 59(2):151-158. PubMed ID: 29327271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune Epilepsy.
    Gaspard N
    Continuum (Minneap Minn); 2016 Feb; 22(1 Epilepsy):227-45. PubMed ID: 26844739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate Receptor Antibodies in Autoimmune Central Nervous System Disease: Basic Mechanisms, Clinical Features, and Antibody Detection.
    Scotton WJ; Karim A; Jacob S
    Methods Mol Biol; 2019; 1941():225-255. PubMed ID: 30707437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurological syndromes, encephalitis].
    Yamamoto T; Tsuji S
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):995-1005. PubMed ID: 20567100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Movement disorders in paraneoplastic and autoimmune disease.
    Panzer J; Dalmau J
    Curr Opin Neurol; 2011 Aug; 24(4):346-53. PubMed ID: 21577108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-mediated disorders.
    Höftberger R; Lassmann H
    Handb Clin Neurol; 2017; 145():285-299. PubMed ID: 28987176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraneoplastic autoimmune movement disorders.
    Lim TT
    Parkinsonism Relat Disord; 2017 Nov; 44():106-109. PubMed ID: 29097081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraneoplastic movement disorders.
    Popławska-Domaszewicz K; Florczak-Wyspiańska J; Kozubski W; Michalak S
    Rev Neurosci; 2018 Sep; 29(7):745-755. PubMed ID: 29561731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune therapy in autoimmune encephalitis: a systematic review.
    Nosadini M; Mohammad SS; Ramanathan S; Brilot F; Dale RC
    Expert Rev Neurother; 2015; 15(12):1391-419. PubMed ID: 26559389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
    Bastiaansen AEM; van Sonderen A; Titulaer MJ
    Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymoma and Autoimmune Encephalitis: Clinical Manifestations and Antibodies.
    Guasp M; Landa J; Martinez-Hernandez E; Sabater L; Iizuka T; Simabukuro M; Nakamura M; Kinoshita M; Kurihara M; Kaida K; Bruna J; Kapetanovic S; Sánchez P; Ruiz-García R; Naranjo L; Planagumà J; Muñoz-Lopetegi A; Bataller L; Saiz A; Dalmau J; Graus F
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34301822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraneoplastic disorders of the CNS and autoimmune synaptic encephalitis.
    Rosenfeld MR; Dalmau JO
    Continuum (Minneap Minn); 2012 Apr; 18(2):366-83. PubMed ID: 22810133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
    Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
    JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
    Jarius S; Metz I; König FB; Ruprecht K; Reindl M; Paul F; Brück W; Wildemann B
    Mult Scler; 2016 Oct; 22(12):1541-1549. PubMed ID: 26869529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Paraneoplastic neurologic syndromes: laboratory diagnostics and immunological aspects].
    Hayden Z; Böröcz K; Csizmadia Z; Kellermayer Z; Balogh P; Berki T
    Magy Onkol; 2019 Sep; 63(3):261-267. PubMed ID: 31533147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraneoplastic neurological syndromes.
    Graus F; Dalmau J
    Curr Opin Neurol; 2012 Dec; 25(6):795-801. PubMed ID: 23041955
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 44.